CBIO
Crescent Biopharma, Inc.
NASDAQ: CBIO · HEALTHCARE · BIOTECHNOLOGY
$22.37
+6.83% today
Updated 2026-04-30
Market cap
$755.46M
P/E ratio
—
P/S ratio
69.67x
EPS (TTM)
$-12.81
Dividend yield
—
52W range
$9 – $29
Volume
0.2M
Crescent Biopharma, Inc. (CBIO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.81M | $15.26M | $3.99M | $15.03M | $20.07M | $18500.00 | — | — | — | $10.16M | $1.16M | $75000.00 | $10000.00 | — | $10.84M |
| Revenue growth (YoY) | — | +300.0% | -73.8% | +276.4% | +33.6% | -99.9% | -100.0% | — | — | — | -88.6% | -93.5% | -86.7% | -100.0% | — |
| Cost of revenue | $83861.00 | — | — | — | — | — | $263541.00 | $275123.00 | $899302.00 | $951599.00 | — | $1.03M | $153301.00 | $35174.00 | $84000.00 |
| Gross profit | $3.73M | $15.26M | $3.99M | $15.03M | $20.07M | $18500.00 | $-263541.00 | $-275123.00 | $-899302.00 | $10.16M | $1.16M | $75000.00 | $10000.00 | $-35174.00 | $10.76M |
| Gross margin | 97.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | — | 99.2% |
| R&D | $7.80M | $9.44M | $11.70M | $19.57M | $25.05M | $23.28M | $24.10M | $40.09M | $47.03M | $44.93M | $47.49M | $28.39M | $20.07M | $56.14M | $138.09M |
| SG&A | — | $2.18M | $2.90M | $6.60M | $7.81M | $8.65M | $9.83M | $11.41M | $14.36M | $16.74M | $17.12M | $19.09M | $19.21M | $12.63M | $25.39M |
| Operating income | $-6.08M | $3.64M | $-10.61M | $-11.14M | $-12.78M | $-31.91M | $-33.93M | $-51.51M | $-61.39M | $-51.51M | $-63.45M | $-47.40M | $-39.28M | $-68.76M | $-152.63M |
| Operating margin | -159.5% | 23.8% | -265.7% | -74.1% | -63.7% | -172505.3% | — | — | — | -506.8% | -5470.7% | -63204.4% | -392752.9% | — | -1407.5% |
| EBITDA | $-6.00M | $3.73M | $-10.47M | $-10.98M | $-12.59M | $-31.72M | $-33.67M | $-51.23M | $-56.99M | $-51.24M | $-63.18M | $-47.20M | $-39.12M | — | $-149.67M |
| EBITDA margin | -157.3% | 24.5% | -262.3% | -73.1% | -62.7% | -171475.4% | — | — | — | -504.2% | -5447.9% | -62927.6% | -391213.5% | — | -1380.2% |
| EBIT | $-6.08M | $3.63M | $-10.61M | $-11.14M | $-12.78M | $-31.91M | $-33.93M | $-51.50M | $-57.89M | $-51.51M | $-63.45M | $-47.40M | $-39.27M | — | $-149.76M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $2.19M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.11M | $3.66M | $-10.61M | $-11.12M | $-12.77M | $-31.81M | $-33.28M | $-48.27M | $-54.12M | $-51.03M | $-63.43M | $-46.69M | $-36.90M | $-71.47M | $-149.94M |
| Net income growth (YoY) | — | +159.8% | -390.1% | -4.9% | -14.8% | -149.1% | -4.6% | -45.0% | -12.1% | +5.7% | -24.3% | +26.4% | +21.0% | -93.7% | -109.8% |
| Profit margin | -160.3% | 24.0% | -265.6% | -74.0% | -63.6% | -171945.1% | — | — | — | -502.1% | -5469.0% | -62251.7% | -368994.2% | — | -1382.7% |